Literature DB >> 9224772

Quantitative brain microdialysis study on the mechanism of quinolones distribution in the central nervous system.

T Ooie1, T Terasaki, H Suzuki, Y Sugiyama.   

Abstract

Brain interstitial fluid (ISF) concentrations, which regulate the toxicodynamic effect of quinolone antimicrobial agents (quinolones) in the central nervous system, have been determined for norfloxacin, ofloxacin, fleroxacin, and pefloxacin using a quantitative brain microdialysis technique. Steady-state brain ISF concentrations of the quinolones were 7-30 times lower than the unbound serum concentrations due to restricted distribution in the brain. Cerebrospinal fluid concentrations of the quinolones were approximately twice as high as the brain ISF concentrations, except for norfloxacin. Thus, it seems that an active efflux transport system across the blood-brain barrier is responsible for maintaining brain ISF concentrations lower than unbound serum concentrations at steady-state. A good correlation was observed for norfloxacin, ofloxacin, fleroxacin, and pefloxacin between brain ISF concentrations and total brain concentrations. Moreover, a relatively small difference was observed among the quinolones for the in vitro brain slice-to-medium concentration ratio, compared with an 11-fold difference in the in vivo brain-to-unbound serum concentration ratio after intravenous infusion. These results indicate that the different quinolones studied all exhibit similar apparent binding and/or uptake by brain parenchyma, with an average brain ISF-to-total brain concentration ratio of 0.688.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9224772

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  16 in total

Review 1.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue.

Authors:  Markus Müller; Amparo dela Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

Review 2.  How to measure drug transport across the blood-brain barrier.

Authors:  Ulrich Bickel
Journal:  NeuroRx       Date:  2005-01

3.  Correlation between quinolone uptakes by BCECs in vitro and brain-to-plasma concentration ratios in rats.

Authors:  X D Liu; D W Wang; L Xie
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Oct-Dec       Impact factor: 2.441

4.  Pharmacokinetics of pefloxacin and its interaction with cyclosporin A, a P-glycoprotein modulator, in rat blood, brain and bile, using simultaneous microdialysis.

Authors:  T H Tsai
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

5.  Characterization of the transport properties of a quinolone antibiotic, fleroxacin, in rat choroid plexus.

Authors:  T Ooie; H Suzuki; T Terasaki; Y Sugiyama
Journal:  Pharm Res       Date:  1996-04       Impact factor: 4.200

6.  Effect of Antibiotic Class on Stroke Outcome.

Authors:  Dannielle Zierath; Allison Kunze; Leia Fecteau; Kyra Becker
Journal:  Stroke       Date:  2015-07-02       Impact factor: 7.914

7.  Evaluation of blood-brain barrier passage of a muscarine M1 agonist and a series of analogous tetrahydropyridines measured by in vivo microdialysis.

Authors:  H H Sveigaard; L Dalgaard
Journal:  Pharm Res       Date:  2000-01       Impact factor: 4.200

8.  Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation.

Authors:  T Ooie; H Suzuki; T Terasaki; Y Sugiyama
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

Review 9.  In silico prediction of brain exposure: drug free fraction, unbound brain to plasma concentration ratio and equilibrium half-life.

Authors:  Morena Spreafico; Matthew P Jacobson
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

10.  Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits.

Authors:  C Ostergaard; T K Sørensen; J D Knudsen; N Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.